Recent News

• 01.29.2026 - MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
• 12.01.2025 - Message from the CEO to MediciNova Shareholders
• 11.18.2025 - MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
• 11.06.2025 - MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
• 10.30.2025 - MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
• 10.06.2025 - MediciNova to Present at the LD Micro Main Event XIX Investor Conference
• 10.06.2025 - MediciNova to Present at the LD Micro Main Event XIX Investor Conference
• 10.06.2025 - MediciNova to Present at the LD Micro Main Event XIX Investor Conference
• 09.22.2025 - MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
• 09.22.2025 - MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)

Recent Filings

• 01.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.30.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.30.2025 - 8-K Current report
• 12.11.2025 - EFFECT Notice of Effectiveness
• 12.05.2025 - S-3 Registration statement under Securities Act of 1933
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 09.30.2025 - EFFECT Notice of Effectiveness